Market and Target Audience
BioNK-c will primarily develop and market its immune cellular therapy products to Brazil.
Brazil’s universal healthcare system presents an exceptional challenge for biologic and cell therapy products.
With a vast population and a commitment to accessible healthcare, the Brazilian market is ground for BioNK-c’s innovative therapies to make a meaningful impact.
Brazil’s health expenditure was over U$ 180 billion in 2021 for its 215 million inhabitant less than U$ 1,124 per capita, against U$ 13,000 in the USA.
Brazil’s Universal Health System is responsible for ½ of the population with a budget of only U$ 32 billion.
Brazil’s Pharma Market
Brazil: valued at approximately USD 19.7 billion in 2023, with projections to grow to USD 42.90 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.20% (Market Research Future) (Fitch Solutions).
Brazil’s biopharmaceutical market has experienced dramatic changes since 2000, with improvements in the performance of local firms, as well as an expansion in consumer demand and productive capacity, which have made the country the sixth largest market in the world. (https://ipc.mit.edu)
The Brazilian drug market has traded BRL 106,78 billion in 2022, equivalent to USD 20.70 billion [Canal Farmácia (Pharmacy Channel), net value – average discount of 37.58 %], according to surveys by consultancy company IQVIA. There was an increase of 16,95 % in BRL, compared to the previous year, representing approximately 2 % of the world market, being the 10th in revenue in the ranking of the 20 main economies. In Latin America, it is the main market, ahead of Mexico, Colombia and Argentina. (Sindusfarma)
Brazil’s Cancer Statistics
704,000 new cases of cancer are expected for the triennium 2023-2025. Except for non-melanoma skin cancer, 483,000 new cases will occur. Female breast cancer and prostate cancer were the most frequent with 73,000 and 71,000 new cases, respectively, followed by colorectal cancer (45,000), lung (32,000) and stomach (21,000), and cervical cancer (17,000).
In Brazil, due to its continental dimensions and heterogeneity both in terms of population and territory, the incidence profile reflects the diversity of geographic regions, and patterns similar to developed and developing countries.
Estimated Cancer Incidence in Brazil, 2023-2025 doi: https://doi.org/10.32635/2176-9745.RBC.2023v69n1.3700
Brazil Market Opportunity
Market Size and Key Findings The Brazil Oncology Drugs market size is at around USD 7.9 billion in 2020 and is projected to reach USD xx billion in 2027, exhibiting a CAGR of 10.9% during the forecast period.
By 2030, it is anticipated that the Brazil oncology drugs market will reach a value of $12.7 Bn from $4.9 Bn in 2022, growing at a CAGR of 12.6%… (Insights 10).